Page last updated: 2024-09-03

gefitinib and Lung Adenocarcinoma

gefitinib has been researched along with Lung Adenocarcinoma in 225 studies

Research

Studies (225)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	164 (72.89)	24.3611
2020's	61 (27.11)	2.80

Authors

Authors	Studies
Fan, G; Li, Q; Liu, G; Liu, X; Lu, J; Shen, X; Wang, F; Wang, S; Zhu, H; Zhu, Y	1
Chang, CC; Chen, YY; Huang, WL; Lai, WW; Tseng, YL; Yen, YT	1
Huang, YS; Liu, J; Peng, Y; Xia, L; Yang, ZZ	1
Lei, S; Li, B; Li, S; Wang, J; Wang, Q; Yu, C; Zhang, Z	1
Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC	1
Li, W; Li, Y; Tian, P; Wang, K	1
Li, M; Lian, R; Wang, L	1
Han, L; He, Y; Hua, H; Xing, H; Yang, M; Zeng, J; Zhang, N	1
Che, G; Li, J; Li, X; Liu, Q; Luo, L; Wang, Y; Xie, X	1
Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH	1
Chang, YC; Chen, MC; Chen, RJ; Huang, CY; Kuo, CH; Kuo, WW; Mhone, TG; Shih, TC; Wang, TF; Yeh, CM	1
Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R	1
Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M	1
Chen, H; Fang, S; Hu, Z; Li, N; Liu, K; Pan, Q; Wei, Y; Xu, G; Xu, S; Zhu, L; Zhu, Y	1
Li, J; Peng, L; Stebbing, J; Zhu, L	1
Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F	1
Igai, H; Kamiyoshihara, M; Matsuura, N; Numajiri, K; Ohsawa, F	1
Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T	1
Hou, M; Huang, L; Li, Y; Liu, J; Shen, W; Zhou, Q	1
Chen, X; Li, D; Miao, K; Shou, T; Zhang, W	1
Igai, H; Kamiyoshihara, M; Numajiri, K; Ohsawa, F	1
Deng, C; He, J; Kang, P; Lan, X; Liu, X; Luo, H; Sun, Z; Wang, Y; Zhao, L; Zhou, X	1
Lai, XY; Shi, YM; Zhou, MM	1
Fang, F; Han, L; Li, J; Long, S; Ma, C; Tang, Q; Wang, R; Wang, S; Wang, X; Wu, W; Xu, M; Yu, Y	1
Bosley, J; Ceres, N; Duruisseaux, M; Jacob, E; Kahoul, R; L'Hostis, A; Lefèvre, L; Monteiro, C; Palgen, JL; Perrillat-Mercerot, A; Peyronnet, E; Toueg, R	1
Guo, Q; Jiang, N; Li, K; Rao, XR; Wu, CY; Zhou, R	1
Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q	1
Chen, J; Chen, Q; Chen, Y; Jiang, C; Jiao, D; Liu, X; Liu, Y; Tang, X	1
Gong, Y; Hua, GD; Huang, M; Lei, ZZ; Liang, Y; Sun, XD; Wang, JG; Wang, Y; Xue, CM; Yang, WH; Zhang, SS; Zhu, BC	1
Bai, J; Cai, S; Chen, H; Gao, C; Han, R; He, Y; Jiang, L; Li, L; Ren, B; Sun, J; Tian, K; Wang, H; Wang, Y; Wu, G; Xiao, HL; Xu, Z; Yang, Z; Zhang, XJ; Zhao, Y; Zhou, Q; Zhou, X	1
Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D	1
Huang, Z; Ma, Y; Si, J; Xiong, Y; Yang, Y; Zhang, P	1
Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Lui, MMS; Tam, TCC	1
Bernardo, S; Bousquet Mur, E; Calvayrac, O; Cañamero, M; Casanova, E; Colinge, J; Fabbrizio, E; Favre, G; Ferrer, I; Giry, A; Glasson, Y; Goussard, M; Mancini, M; Maraver, A; Mazieres, J; Moll, HP; Papon, L; Paz-Ares, L; Pirot, N; Pujol, JL; Quantin, X; Siebel, CW; Soria, JC; Turtoi, A; Wong, KK; Yarden, Y	1
Bi, JW; Li, S; Lv, C; Ma, Y; Si, J; Wu, N; Xiong, Y; Yang, Y	1
Ikeda, M; Kawakami, K; Kobayashi, S; Nomura, M; Ohta, S; Sato, E; Takahashi, T	1
Ge, D; Gu, J; Liu, Z; Lu, C; Mao, W; Shou, H; Xu, F; Zhang, K; Zhang, Z; Zhu, Q	1
Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C	1
Chen, Y; Feng, J; Li, X; Qin, X; Sha, H; Shi, M; Yu, S	1
Azuma, Y; Iijima, M; Kosaka, T; Kuwano, H; Mogi, A; Shimizu, K; Shirabe, K; Yajima, T; Yokobori, T	1
Wang, A; Yi, J; Zhang, X; Zhang, Y; Zhu, M	1
Cui, H; Gong, X; Jin, X; Li, F; Wang, J; Wang, W	1
Deng, Q; He, D; Wang, F; Xie, Z; Yang, H	1
Jiang, Y; Li, D; Li, Y; Liao, X; Liu, N; Qin, D; Tang, J; Wang, Y; Yin, T; Yu, M	1
Fukuda, K; Kodama, K; Nanjyo, H; Shibata, H; Shimazu, K; Taguchi, D; Takahashi, S; Takahashi, T; Yoshida, T	1
An, HJ; Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Nam, BH	1
Feng, J; Huang, J; Li, C; Pan, B; Xia, G; Zhu, J	1
Brat, K; Jakubíková, L; Šťastná, N	1
Chang, CL; Chiou, TJ; Chuang, SE; Hsia, S; Hu, MH; Lai, GM; Liao, CH; Liu, YR; Tsai, WL; Tzeng, YT; Wang, LM; Whang-Peng, J; Yao, CJ	1
Li, Y; Liu, J; Song, Y; Yang, M; Yu, J; Zhang, L; Zhang, N	1
Chen, D; Li, S; Liu, Y; Wei, Q; Zhang, J	1
Li, Y; Lou, L; Lv, F; Shen, H; Wang, G; Wang, J; Xing, L; Zhang, X	1
An, T; Bai, H; Cheng, Y; Chuai, S; Ding, C; Duan, J; Gao, H; Han, J; Hu, Y; Huang, C; Liang, L; Peng, F; Shi, Y; Song, Y; Tian, Y; Wang, D; Wang, J; Wang, K; Wang, Z; Wu, YL; Xu, J; Yang, Z; Ye, J; Zhang, L; Zhao, J; Zhou, C; Zhou, Q; Zhu, G	1
Gomi, K; Hachiya, T; Hama, M; Hirabayashi, T; Kimoto, M; Tanaka, S	1
Gao, F; Guo, R; Qu, T; Wang, Q; Wei, J; Zhang, C; Zhang, J	1
Gu, P; Han, B; Lou, Y; Lu, J; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H	1
Liu, N; Yu, M; Zhang, S; Zheng, L	1
Bie, Y; Liao, J; Lin, H; Wang, D; Wang, J; Xiong, L; Zhang, Y	1
Gotoh, N; Horike, SI; Kohno, T; Li, M; Meguro-Horike, M; Nakata, A; Nishimura, T; Takeuchi, Y; Wang, Y; Yiming, R	1
Chen, C; Guo, ZX; Hu, WD; Liu, XP; Song, CK; Wang, AF; Wang, QW; Wang, YJ; Yao, J; Yu, DH	1
Bu, T; Xu, A; Yan, H	1
Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y	1
Li, J; Li, X; Wang, X; Xia, P; Yuan, L; Zhang, G; Zhao, S	1
Chang, GC; Chen, JJW; Chen, KC; Chin, CS; Hsu, KH; Huang, YH; Su, KY; Tseng, JS; Yang, TY; Yu, SL	1
Chen, C; Deng, J; Hu, X; Li, S; Liu, Z; She, Y; Sun, X; Wang, T; Xie, D; Zhao, M; Zhong, Y	1
Mi, J; Xu, Q; Zhang, Y	1
Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L	1
Goto, K; Hashimoto, H; Ishibashi, M; Ishii, G; Kirita, K; Masutomi, K; Matsumoto, S; Miyashita, T; Nakamura, Y; Neri, S; Niho, S; Ochiai, A; Tsuboi, M; Udagawa, H; Umemura, S; Yoh, K; Yoshida, T	1
Al-Lazikani, B; Marti-Renom, MA; Martínez-Jiménez, F; Overington, JP	1
Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M	1
Chong, IW; Chou, SH; Hsu, JS; Huang, MS; Hung, JY; Lee, JY; Liu, TC; Tsai, MJ; Wu, KL; Yang, CJ	1
Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L	1
Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY	1
Arata, S; Ohba, M; Ohmori, T; Yamaoka, T	1
Jing, YT; Li, YQ; Liu, YS; Wang, Z; Wu, SC; Yan, JP; Yang, Y; Ying, XW; Zhou, HB	1
Kuwano, H; Mogi, A; Nakazawa, S; Shimizu, K	1
Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL	1
Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ	1
Akizuki, R; Endo, S; Ikari, A; Maruhashi, R; Matsunaga, T; Sakai, H; Sato, T; Yamaguchi, M; Yamazaki, Y	1
Yang, M; Yin, L; Yuan, J; Zhang, L; Zhang, N; Zhou, L; Zhu, H	1
Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V	1
Cao, H; Ding, L; Feng, J; Li, H; Liu, S; Ma, R; Ni, J; Wang, Z; Wu, J; Zhang, XQ; Zhao, X; Zhou, LL	1
Li, B; Yang, M; Yuan, J; Zhang, L; Zhang, N; Zhou, L; Zhu, H	1
Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y	1
Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H	1
Huang, J; Wang, J; Wang, Y; Zhai, Y	1
Chang, CL; Chang, JH; Chang, YC; Chow, JM; Hsu, HL; Lin, WC; Wu, ATH; Wu, SY; Yen, YC; Yuan, KS	1
Chai, Y; Wu, Y; Yao, Y; Zhu, Z	1
Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T	1
Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Zhou, J	1
DU, JX; Gong, WX; Huang, SC; Liang, CW; Pan, Y; Peng, DX; Quan, W; Wang, X; Xie, Y; Zhang, N; Zheng, LP	1
Aigner, P; Barbacid, M; Brcic, L; Casanova, E; Dezso, K; Dome, B; Eferl, R; Grabner, B; Győrffy, B; Hidalgo, M; Hruschka, N; Laszlo, V; Lopez-Casas, PP; Mohrherr, J; Moldvay, J; Moll, HP; Moriggl, R; Musteanu, M; Penninger, J; Popper, H; Pranz, K; Schramek, D; Sibilia, M; Stiedl, P; Stoiber, D	1
Gu, J; Jin, Y; Liang, X; Liu, T; Ma, H; Ma, X; Tao, J; Yang, T	1
Chen, T; Li, R; Tu, J; Zhang, P	1
Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J	1
Karachaliou, N; Rosell, R	1
Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I	1
Li, J; Li, Y; Pan, W; Yang, M; Zhang, L; Zhang, N; Zhu, H	1
Kenzaka, T; Miyoshi, K; Nakaji, H	1
Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y	1
Cao, L; Huang, J; Jiang, Y; Li, N; Xu, B; Zhang, J; Zhao, M	1
Agazzi, GM; Berruti, A; Bettoni, V; Borghesi, A; Caprioli, A; Farina, D; Ganeshan, B; Maroldi, R; Ravanelli, M; Roca, E; Tononcelli, E	1
Jin, L; Tao, L; Zhu, J	1
Li, Y; Pan, Y; Yang, M; Yu, J; Zhang, L; Zhang, N; Zheng, Y	1
Dong, SH; Feng, LX; Song, SA; Wang, J; Yu, HS; Yu, Z; Zhai, WX; Zhang, Y	1
Li, W; Li, Y; Luo, W; Song, J; Tian, P; Zhang, R; Zhou, Y	1
Han, C; Hou, T; Hu, C; Hu, H; Liu, J; Ma, J; Peng, H; Que, K; Zhang, N	1
Bourgoin-Voillard, S; Coll, JL; Cunin, V; Hurbin, A; Lehmann, SG; Michelland, S; Seve, M; Vanwonterghem, L	1
Csabai, I; Glasz, T; Krzystanek, M; Moldvay, J; Németh, E; Pipek, O; Reiniger, L; Ribli, D; Szallasi, Z; Sztupinszki, Z; Szüts, D	1
Han, R; Jia, Y; Jiang, T; Li, X; Liu, S; Liu, X; Luo, J; Qiao, M; Ren, S; Shi, J; Su, C; Zhang, L; Zhao, C; Zhao, S; Zhou, C	1
Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J	1
Amato, M; D'Angelillo, RM; Fiore, M; Perrone, G; Ramella, S; Righi, D; Trecca, P; Trodella, L	1
Itano, K; Ito, T; Kawasaki, S; Kumagai, Y; Maruyama, T; Murakami, Y; Suzuki, T; Tamura, K	1
Kagohashi, K; Ohara, G; Okauchi, S; Sasatani, Y; Satoh, H	1
Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK	1
Hou, YH; Pan, JB; Zhang, GJ	1
Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C	1
Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM	1
Lazarus, DR; Ost, DE	1
Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J	1
Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N	1
Aurisicchio, L; Ciliberto, G; Coluccia, P; D'Andrilli, A; De Vitis, C; Fattore, L; Giovagnoli, MR; Luberto, L; Malpicci, D; Mancini, R; Marra, E; Normanno, N; Noto, A; Roscilli, G; Ruco, L	1
Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T	1
Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H	1
Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S	1
Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O	1
Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G	1
Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T	1
Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP	1
Borczuk, AC; Siegelin, MD	1
Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A	1
Funakoshi, Y; Maeda, H; Takeuchi, Y	1
Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W	1
Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K	1
Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS	1
Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H	1
Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Sun, Y; Wang, H; Wang, Y; Wang, Z; Zhang, X	1
Costa, DB; Gandhi, L; Gerber, DE	1
Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L	1
Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M	1
Chen, HW; Chen, WJ; Ho, CC; Ho, CL; Hsieh, WY; Lee, JY; Li, LH; Li, PR; Wang, CC; Wu, P; Yang, SM; Yen, MY	1
Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z	1
Bi, F; Ge, X; Huang, M; Wang, Y; Zheng, L	1
Goto, K; Hashimoto, H; Iida, S; Ishii, G; Matsumoto, S; Nagai, K; Neri, S; Niho, S; Niimi, A; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T	1
Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q	1
Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H	1
Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB	1
Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ	1
Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA	1
Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y	1
Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H	1
Gemma, A; Kitamura, K; Kosaihira, S; Kubota, K; Matsuda, K; Matsumoto, M; Minegishi, Y; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T; Yoshimura, A; Zou, F	1
Amato, E; Bria, E; Brunelli, M; Chilosi, M; Corbo, V; Fassan, M; Giglioli, E; Kinspergher, S; Milella, M; Novello, S; Peretti, U; Pilotto, S; Righi, L; Santo, A; Scarpa, A; Sperduti, I; Tortora, G; Vavalà, T	1
Hu, C; Li, M; Wang, Q	1
Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S	1
Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB	1
Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL	1
Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L	1
Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X	1
Liu, G; Liu, H; Ma, T; Zhang, X	1
Chen, Z; Wu, JH; Zhang, X; Zhao, J	1
Du, LW; Feng, JG; Jiang, H; Li, JH; Ma, SL; Song, SC; Zhao, PJ; Zhou, GH; Zhu, XH	1
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W	1
Chen, L; Li, Q; Peng, S; Wang, R; Wang, W; Yang, H	1
Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K	1
Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM	1
Chen, C; Lian, ZZ; Sun, YF	1
Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H	1
Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H	1
Gong, J; Hu, P; Sun, S; Tang, F; Wang, Y; Wang, Z; Xie, C	1
Chang, GC; Close, S; Garrus, JE; Geater, SL; Han, M; Komarnitsky, P; Mok, TS; Park, K; Payumo, F; Su, WC; Tan, EH; Yang, JC	1
Creighton, CJ; Deng, B; Gibbons, DL; Guo, L; Lu, Q; Molina, JR; Sun, Z; Yang, P; Yang, Y; Yi, ES; Zhang, T	1
Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yukawa, T	1
Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J	1
Arata, S; Hirose, T; Ishida, H; Kishino, Y; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Shirai, T; Yamaoka, T	1
Nakamura, H; Nishimura, T	1
Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N	1
Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G	1
Bashir, ES; Chan, CY; Kwan, AK; Mun Keong, K	1
Urata, Y	1
Chang, CH; Lee, CH; Wang, JY	1
Lam, KC; Mok, TS	1
Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y	1
Asamura, H; Furuta, K; Kohno, T; Kozu, Y; Sekine, I; Suzuki, K; Tamura, T; Tsuda, H; Tsuta, K; Watanabe, S; Yokota, J; Yoshida, A	1
Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L	1
Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K	1
Han, JH; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, YJ; Park, JH; Yoon, KA; Yoon, SJ; Yun, T	1
Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K	1
Morio, A; Ninomiya, H; Sunada, K	1
Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A	1
Wang, L; Xiao, F; Zhang, W; Zheng, J	1
Antoine, M; Brambilla, E; Busser, B; Cadranel, J; Coll, JL; de Fraipont, F; Dufort, S; Hurbin, A; Moro-Sibilot, D; Rabbe, N; Tenaud, C; Wislez, M	1
Li, Y; Liu, B; Qin, X; You, J; Zhou, Q	1
Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M	1
Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Yoon, KA; Yun, T	1
Shepherd, FA	1
Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC	1
Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL	1
Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C	1
de Lima Lopes, G; Do, YK; Finkelstein, EA; Mok, T; Segel, JE; Tan, DS	1
He, CS; Hu, ZH; Liu, JL; Tian, Y; Xie, M; Xu, F; Zhang, L; Zhao, LP	1
Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B	1
Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X	1
Chen, W; Hu, CP; Liu, JK; Lu, RL; Xiong, Z; Zhou, H; Zhou, ML	1
Atagi, S; Fukuoka, M; Ichinose, Y; Ishikura, S; Niho, S; Ohe, Y; Okamoto, H; Saijo, N; Shibata, T; Takeda, K; Tamura, T; Yokoyama, A	1
Liu, G; Wang, W; Zhang, X; Zhu, X	1
Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X	1
Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA	1
Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N	1
Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL	1
Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T	1
Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX	1
Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W	1
Chua, KT; Lee, CH; Liam, CK; Lim, BK; Pang, YK; Ruthranesan, M	1
Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C	1
Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ	1
Hashisako, M; Ikegame, S; Kajiki, A; Kumazoe, H; Nagata, N; Wakamatsu, K	1
Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y	1
Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H	1
Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y	1
Jeon, WI; Lee, SY; Ryu, PD	1
Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S	1
Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N	1

Reviews

9 review(s) available for gefitinib and Lung Adenocarcinoma

Article	Year
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews. Medicine, 2023, Nov-10, Volume: 102, Issue:45 Topics: Adenocarcinoma of Lung; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deafness; ErbB Receptors; Female; Gefitinib; Hearing Loss, Sensorineural; Humans; Lung Neoplasms; Mutation	2023
Successful treatment of advanced lung adenocarcinoma complicated with Lambert-Eaton myasthenic syndrome: A case report and literature review. Thoracic cancer, 2020, Volume: 11, Issue:5 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Gefitinib; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Prognosis	2020
Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review. Clinical lung cancer, 2019, Volume: 20, Issue:3 Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Remission Induction	2019
How and when to use genetic markers for nonsmall cell lung cancer. Current opinion in pulmonary medicine, 2013, Volume: 19, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases	2013
Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction	2014
Management and future directions in non-small cell lung cancer with known activating mutations. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases	2014
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature. Medicine, 2016, Volume: 95, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma	2016
Targeted therapy: an evolving world of lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2011
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases	2011

Trials

23 trial(s) available for gefitinib and Lung Adenocarcinoma

Article	Year
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). International journal of clinical oncology, 2023, Volume: 28, Issue:1 Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2023
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23 Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Prognosis; Survival Rate	2019
First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. Clinical lung cancer, 2020, Volume: 21, Issue:6 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Pemetrexed; Prognosis; Smokers; Survival Rate	2020
Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC. Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:1(Special) Topics: Adenocarcinoma of Lung; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Endoglin; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Keratin-19; Lung Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Pemetrexed; Th1-Th2 Balance; Vascular Endothelial Growth Factor A	2021
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial. International journal of cancer, 2017, 09-15, Volume: 141, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines	2017
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines	2013
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome	2013
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome	2014
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma]. Zhonghua yi xue za zhi, 2014, Aug-13, Volume: 94, Issue:30 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking	2014
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome	2014
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies. International journal of oncology, 2015, Volume: 46, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine	2015
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Mar-16, Volume: 16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult	2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-20, Volume: 34, Issue:27 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines	2016
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines	2016
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting. Talanta, 2016, Nov-01, Volume: 160 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2016
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of pathology, 2011, Volume: 225, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Proteins; Quinazolines; Receptor, IGF Type 1; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured	2011
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell-Free System; DNA; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Smoking; Treatment Outcome	2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome	2011
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer, 2012, Feb-15, Volume: 118, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Cost-Benefit Analysis; ErbB Receptors; Gefitinib; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Pharmacogenetics; Quality-Adjusted Life Years; Quinazolines; Singapore; Treatment Outcome	2012
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumonia; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine	2012
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult	2012
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines	2012
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur	2013

Other Studies

193 other study(ies) available for gefitinib and Lung Adenocarcinoma

Article	Year
Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report. Anti-cancer drugs, 2022, 01-01, Volume: 33, Issue:1 Topics: Adenocarcinoma of Lung; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Eruptions; Female; Gefitinib; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lung Neoplasms; Lymphatic Metastasis; Middle Aged	2022
Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs. Thoracic cancer, 2021, Volume: 12, Issue:20 Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Surgical Procedures; Salvage Therapy	2021
Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report. Medicine, 2021, Oct-01, Volume: 100, Issue:39 Topics: Adenocarcinoma of Lung; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Stomach Neoplasms	2021
miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer. Annals of clinical and laboratory science, 2021, Volume: 51, Issue:5 Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lung Neoplasms; Membrane Proteins; Mice, Nude; MicroRNAs; Prognosis; Proteins; Xenograft Model Antitumor Assays	2021
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study. Thoracic cancer, 2021, Volume: 12, Issue:23 Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies	2021
Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report. Clinical lung cancer, 2022, Volume: 23, Issue:1 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Crizotinib; Destrin; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met	2022
Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study. Histology and histopathology, 2022, Volume: 37, Issue:7 Topics: Adenocarcinoma of Lung; Animals; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; MicroRNAs; Proliferating Cell Nuclear Antigen; RNA, Circular	2022
The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Life sciences, 2022, May-01, Volume: 296 Topics: 3' Untranslated Regions; Adenocarcinoma of Lung; Adenosine Deaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; RNA-Binding Proteins	2022
Ureteral metastasis of small cell lung cancer transformed from lung adenocarcinoma: A case report. Thoracic cancer, 2022, Volume: 13, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Small Cell Lung Carcinoma	2022
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. Scientific reports, 2022, 04-29, Volume: 12, Issue:1 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines	2022
Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity. International journal of biological sciences, 2022, Volume: 18, Issue:9 Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoflavones; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species	2022
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications. Cytopathology : official journal of the British Society for Clinical Cytology, 2022, Volume: 33, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors	2022
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma. Immunotherapy, 2022, Volume: 14, Issue:16 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines	2022
Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs. Medicine, 2022, Sep-23, Volume: 101, Issue:38 Topics: Adenocarcinoma of Lung; Algorithms; Antineoplastic Agents; Computational Biology; CTLA-4 Antigen; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding	2022
Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation. Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:5 Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome	2022
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma. Frontiers in immunology, 2022, Volume: 13 Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment	2022
[Multidisciplinary Treatment for Postoperative Recurrent Patients-Report of a Long-Term Survivor]. Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:10 Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Nivolumab; Pemetrexed; Survivors	2022
[STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022, Nov-20, Volume: 25, Issue:11 Topics: Adenocarcinoma of Lung; Animals; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspase 9; Cyclin D1; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt	2022
Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. Medicine, 2023, Jan-27, Volume: 102, Issue:4 Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Small Cell Lung Carcinoma	2023
[Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Octogenarians; Quinazolines	2023
CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. BMC cancer, 2023, Mar-23, Volume: 23, Issue:1 Topics: Adenocarcinoma of Lung; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis	2023
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis. The Kaohsiung journal of medical sciences, 2023, Volume: 39, Issue:7 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species	2023
FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma. Journal of ethnopharmacology, 2024, Jan-10, Volume: 318, Issue:Pt A Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Signal Transduction	2024
Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma. NPJ systems biology and applications, 2023, 07-31, Volume: 9, Issue:1 Topics: Adenocarcinoma of Lung; Animals; Disease Progression; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors	2023
A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients. Aging, 2023, 09-21, Volume: 15, Issue:18 Topics: Adenocarcinoma of Lung; Aurora Kinase A; Gefitinib; Humans; Lung Neoplasms; Prognosis; Tumor Microenvironment	2023
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation. Investigational new drugs, 2023, Volume: 41, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2023
Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma. Biochemical and biophysical research communications, 2023, 11-19, Volume: 682 Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2023
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific journal of cancer prevention : APJCP, 2019, 08-01, Volume: 20, Issue:8 Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate	2019
Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma. Anti-cancer drugs, 2020, Volume: 31, Issue:1 Topics: Adenocarcinoma of Lung; Amidohydrolases; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; RNA, Long Noncoding; Up-Regulation	2020
Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma. Anti-cancer drugs, 2019, Volume: 30, Issue:10 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Retrospective Studies; Treatment Outcome	2019
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. The Journal of clinical investigation, 2020, 02-03, Volume: 130, Issue:2 Topics: Acrylamides; Adenocarcinoma of Lung; Amino Acid Substitution; Aniline Compounds; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Lung Neoplasms; Mice; Mice, Transgenic; Mutation, Missense; Neoplasm Proteins; Protein Kinase Inhibitors; STAT3 Transcription Factor; Transcription Factor HES-1	2020
Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. Journal of experimental & clinical cancer research : CR, 2019, Dec-04, Volume: 38, Issue:1 Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Kinase Inhibitors; Transfection	2019
Tetrandrine Increases the Sensitivity of Human Lung Adenocarcinoma PC14 Cells to Gefitinib by Lysosomal Inhibition. Anticancer research, 2019, Volume: 39, Issue:12 Topics: Adenocarcinoma of Lung; Autophagy; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lysosomes; Microtubule-Associated Proteins	2019
Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Receptors, CXCR4; RNA, Small Interfering; Smad2 Protein; Transforming Growth Factor beta1; Up-Regulation	2020
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 141 Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult	2020
EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene, 2020, Volume: 39, Issue:13 Topics: Adenocarcinoma of Lung; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Drug Resistance, Neoplasm; ErbB Receptors; Exosomes; Female; Gefitinib; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Pneumonectomy; Sequence Deletion; Tumor Escape; Xenograft Model Antitumor Assays	2020
Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells. Surgery today, 2020, Volume: 50, Issue:9 Topics: Adenocarcinoma of Lung; Cell Communication; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Molecular Targeted Therapy; Up-Regulation	2020
Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells. Oncology reports, 2020, Volume: 43, Issue:5 Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Antigens, CD; Cadherins; Cell Proliferation; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Epoxy Compounds; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Phenanthrenes; Xenograft Model Antitumor Assays	2020
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation. Clinical & experimental metastasis, 2020, Volume: 37, Issue:3 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Young Adult	2020
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations. Signal transduction and targeted therapy, 2020, 05-27, Volume: 5, Issue:1 Topics: Adenocarcinoma of Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Retrospective Studies	2020
Lung adenocarcinoma in a patient with Li-Fraumeni syndrome bearing a novel germ-line mutation, TP53R333Vfs12. Japanese journal of clinical oncology, 2020, Sep-28, Volume: 50, Issue:10* Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aniline Compounds; Bone Neoplasms; Female; Gefitinib; Germ-Line Mutation; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Male; Pedigree; Protein Kinase Inhibitors; Tumor Suppressor Protein p53	2020
LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. Cell death & disease, 2020, 07-13, Volume: 11, Issue:7 Topics: A549 Cells; Adenocarcinoma of Lung; Animals; ATP Binding Cassette Transporter, Subfamily B; ErbB Receptors; Gefitinib; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Transfection; Up-Regulation	2020
Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2020,Spring, Volume: 33, Issue:3 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Bevacizumab; Carboplatin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Salvage Therapy	2020
Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells. Marine drugs, 2020, Jul-29, Volume: 18, Issue:8 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Epithelial-Mesenchymal Transition; Fatty Acids, Omega-3; Gefitinib; Humans; Lung Neoplasms; Neoplastic Stem Cells; Selenium	2020
Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma. Carcinogenesis, 2020, 09-24, Volume: 41, Issue:9 Topics: Adenocarcinoma of Lung; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cohort Studies; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; HSP110 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tumor Cells, Cultured	2020
Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 148 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors	2020
Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). Cellular oncology (Dordrecht), 2021, Volume: 44, Issue:1 Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Vault Ribonucleoprotein Particles; Y-Box-Binding Protein 1	2021
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:12 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors	2020
Gefitinib Treatment Was Unsuccessful for Central Diabetes Insipidus Due to Pituitary Metastasis of Lung Adenocarcinoma. Internal medicine (Tokyo, Japan), 2021, Apr-01, Volume: 60, Issue:7 Topics: Adenocarcinoma of Lung; Deamino Arginine Vasopressin; Diabetes Insipidus; Diabetes Insipidus, Neurogenic; Diabetes Mellitus; Gefitinib; Humans; Lung Neoplasms	2021
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. Journal of cellular and molecular medicine, 2021, Volume: 25, Issue:5 Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Methylation; Methyltransferases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction	2021
Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. Cell death & disease, 2021, 02-10, Volume: 12, Issue:2 Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Filamins; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glutathione Transferase; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Mutation; Pemetrexed; Phosphate-Binding Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays	2021
Epidermal growth factor receptor-mutant pulmonary adenocarcinoma coexisting with tuberculosis: A case report. Medicine, 2021, Feb-26, Volume: 100, Issue:8 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Anti-Bacterial Agents; Antineoplastic Agents; Antitubercular Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Tuberculosis, Pulmonary	2021
Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report. Medicine, 2021, Mar-19, Volume: 100, Issue:11 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Pharmacogenomic Variants	2021
MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. Cancer science, 2021, Volume: 112, Issue:9 Topics: A549 Cells; Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Nanog Homeobox Protein; Protein Kinase Inhibitors; RNA-Binding Proteins; Transcriptome; Transfection; Up-Regulation	2021
Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation. Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:11 Topics: A549 Cells; Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Osteopontin; Phosphorylation; Protein Kinase Inhibitors	2021
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU. Chest, 2022, Volume: 161, Issue:1 Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate	2022
Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification. The oncologist, 2021, Volume: 26, Issue:11 Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cetuximab; DNA, Intergenic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms	2021
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. Cancer research and treatment, 2022, Volume: 54, Issue:2 Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors	2022
A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer letters, 2021, 11-01, Volume: 520 Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase Kinase 5; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Circular; Xenograft Model Antitumor Assays	2021
Lung adenocarcinoma presents with diffuse bone metastasis. Thoracic cancer, 2021, Volume: 12, Issue:19 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Zoledronic Acid	2021
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction	2017
CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Scientific reports, 2017, 04-21, Volume: 7 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, CD; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Survival; Coculture Techniques; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; RNA Interference	2017
Rational design of non-resistant targeted cancer therapies. Scientific reports, 2017, 04-24, Volume: 7 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Neoplasm Proteins; Point Mutation	2017
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters. Cancer science, 2017, Volume: 108, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays	2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. BMC pharmacology & toxicology, 2017, 05-10, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy	2017
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 110 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome	2017
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure. Journal of visualized experiments : JoVE, 2017, 08-11, Issue:126 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfones	2017
Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro. Biotechnology progress, 2018, Volume: 34, Issue:1 Topics: ADAM17 Protein; Adenocarcinoma of Lung; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Phosphorylation; RNA Interference	2018
Segmentectomy of the left superior segment (S The Journal of thoracic and cardiovascular surgery, 2018, Volume: 155, Issue:3 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Computed Tomography Angiography; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Metastasectomy; Multiple Pulmonary Nodules; Mutation; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Reoperation; Time Factors; Treatment Outcome; Tumor Burden	2018
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway. Experimental cell research, 2017, 12-15, Volume: 361, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones	2017
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. AJR. American journal of roentgenology, 2018, Volume: 210, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult	2018
Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models. Biochimica et biophysica acta. Molecular cell research, 2018, Volume: 1865, Issue:3 Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Claudin-2; Doxorubicin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Quinazolines; Spheroids, Cellular	2018
Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib. Scientific reports, 2017, 12-19, Volume: 7, Issue:1 Topics: A549 Cells; Adenocarcinoma of Lung; Aged; Alleles; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis	2017
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report. Experimental oncology, 2017, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed	2017
Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells. Cancer medicine, 2018, Volume: 7, Issue:5 Topics: Adenocarcinoma of Lung; ATP Binding Cassette Transporter 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; PPAR gamma; Sulfonamides; Thiazolidinediones	2018
Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clinical lung cancer, 2018, Volume: 19, Issue:4 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bcl-2-Like Protein 11; Drug Resistance, Neoplasm; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Progression-Free Survival; Sequence Deletion	2018
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma. International journal of nanomedicine, 2018, Volume: 13 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results	2018
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report. Medicine, 2018, Volume: 97, Issue:15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid	2018
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. Thoracic cancer, 2018, Volume: 9, Issue:6 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors	2018
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018, Volume: 129, Issue:1 Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors	2018
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine, 2018, Volume: 97, Issue:18 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma	2018
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncology reports, 2018, Volume: 40, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A	2018
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest. Respiratory research, 2018, 05-21, Volume: 19, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines	2018
[Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018, May-20, Volume: 38, Issue:5 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; NF-kappa B p50 Subunit; Proline; Thiocarbamates; Transcription Factor RelA	2018
Afatinib restrains K-RAS-driven lung tumorigenesis. Science translational medicine, 2018, 06-20, Volume: 10, Issue:446 Topics: Adenocarcinoma of Lung; Afatinib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction	2018
[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018, Jun-20, Volume: 21, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Oxidoreductases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines	2018
Hemorrhagic Cystitis Associated With Gefitinib Treatment: A Case Report. Urology, 2018, Volume: 120 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cystitis; Cystoscopy; Gefitinib; Humans; Lung Neoplasms; Male; Tomography, X-Ray Computed; Urinalysis; Urinary Bladder	2018
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 47, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin	2018
Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma. The Lancet. Respiratory medicine, 2018, Volume: 6, Issue:9 Topics: Adenocarcinoma of Lung; Circulating Tumor DNA; ErbB Receptors; Gefitinib; Genomics; Humans; Lung Neoplasms; Mutation	2018
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Internal medicine (Tokyo, Japan), 2018, Dec-01, Volume: 57, Issue:23 Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2018
Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and cell biology, 2018, Volume: 37, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Telomere	2018
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis. BMJ case reports, 2018, Oct-12, Volume: 2018 Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure	2018
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clinical lung cancer, 2019, Volume: 20, Issue:1 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis	2019
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study. BMC pulmonary medicine, 2018, Nov-20, Volume: 18, Issue:1 Topics: Adenocarcinoma of Lung; Adult; Aged; Asian People; Brain Neoplasms; China; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis	2018
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). European journal of radiology, 2018, Volume: 109 Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Retrospective Studies; Tomography, X-Ray Computed	2018
MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1. Molecular medicine reports, 2019, Volume: 19, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Phosphoproteins; RNA, Messenger; Transcription Factors; YAP-Signaling Proteins	2019
miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs. Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:4 Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors	2019
Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Biomarkers, Tumor; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Survival Rate	2019
[Effect of down-regulation of growth arrest and DNA damage inducible protein 45β on PC9 lung adenocarcinoma cells]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2018, Nov-28, Volume: 43, Issue:11 Topics: Adenocarcinoma of Lung; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gefitinib; Humans; RNA, Small Interfering	2018
A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin. Journal of proteomics, 2019, 03-20, Volume: 195 Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Proteomics; Proto-Oncogene Proteins p21(ras)	2019
The genomic imprint of cancer therapies helps timing the formation of metastases. International journal of cancer, 2019, 08-01, Volume: 145, Issue:3 Topics: Adenocarcinoma of Lung; Algorithms; Cisplatin; ErbB Receptors; Gefitinib; Gene Rearrangement; Genome-Wide Association Study; Genomic Imprinting; Humans; Lung Neoplasms; Models, Genetic; Mutagenesis; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies	2019
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies. International journal of cancer, 2019, 09-01, Volume: 145, Issue:5 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Animals; Antineoplastic Agents; B7-H1 Antigen; Cytokines; Disease Models, Animal; ErbB Receptors; Gefitinib; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Mice, Transgenic; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Random Allocation; Tumor Microenvironment	2019
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway. Journal of experimental & clinical cancer research : CR, 2019, Feb-21, Volume: 38, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation	2019
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma. Tumori, 2019, Volume: 105, Issue:6 Topics: Adenocarcinoma of Lung; Biomarkers; Biopsy; Cell Transformation, Neoplastic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Multimodal Imaging; Mutation; Protein Kinase Inhibitors; Radiotherapy; Small Cell Lung Carcinoma	2019
Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification. Biochemical and biophysical research communications, 2019, 04-09, Volume: 511, Issue:3 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Models, Biological; Proto-Oncogene Proteins c-met	2019
Prolonged response after the discontinuation of nivolumab after resistance to gefitinib. The clinical respiratory journal, 2019, Volume: 13, Issue:10 Topics: Adenocarcinoma of Lung; Adrenal Insufficiency; Aged; Antineoplastic Agents, Immunological; Central Nervous System Neoplasms; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Nivolumab; Protein Kinase Inhibitors; Treatment Outcome; Withholding Treatment	2019
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma. Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2013
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines	2013
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases	2013
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction	2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome	2013
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget, 2013, Volume: 4, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays	2013
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome	2013
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy	2013
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. International journal of oncology, 2013, Volume: 43, Issue:6 Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays	2013
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform The Journal of molecular diagnostics : JMD, 2014, Volume: 16, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA	2014
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib. Journal of Korean medical science, 2013, Volume: 28, Issue:11 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome	2013
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma. Pathology oncology research : POR, 2014, Volume: 20, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult	2014
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-20, Volume: 32, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma. Asian cardiovascular & thoracic annals, 2013, Volume: 21, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2013
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochemical and biophysical research communications, 2014, Mar-28, Volume: 446, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm	2014
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia. BMJ case reports, 2014, Mar-13, Volume: 2014 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines	2014
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 84, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome	2014
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma. The Journal of pathology, 2014, Volume: 234, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines	2014
[Efficacy of gefitinib for young patients with unknown EGFR gene mutation  in advanced lung adenocarcinoma]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2014, Volume: 17, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2014
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Targeted oncology, 2015, Volume: 10, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry	2015
Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PloS one, 2014, Volume: 9, Issue:8 Topics: Acridine Orange; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antineoplastic Agents, Phytogenic; Autophagy; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cupressaceae; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Gas Chromatography-Mass Spectrometry; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Monoterpenes; Oils, Volatile; Quinazolines; Real-Time Polymerase Chain Reaction; Taiwan; Tropolone; Tumor Stem Cell Assay	2014
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells. Molecular medicine reports, 2014, Volume: 10, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines	2014
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Molecular medicine reports, 2015, Volume: 11, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results	2015
Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Feb-01, Volume: 21, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblasts; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mutation; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Risk Factors; Treatment Outcome; Tumor Microenvironment	2015
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung? APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA	2015
Disease flare after gefitinib discontinuation. Respiratory investigation, 2015, Volume: 53, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment	2015
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung cancer (Amsterdam, Netherlands), 2015, Volume: 88, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2015
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature communications, 2015, Mar-11, Volume: 6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides	2015
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines	2015
Current two EGFR mutations in lung adenocarcinoma - case report. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2015, Volume: 28, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography	2015
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC cancer, 2015, Feb-06, Volume: 15 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines	2015
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget, 2015, May-20, Volume: 6, Issue:14 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Proportional Hazards Models; Quinazolines; Sequence Analysis, DNA	2015
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Volume: 18, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines	2015
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting	2015
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicology and applied pharmacology, 2015, Nov-01, Volume: 288, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2015
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays	2015
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Sep-20, Volume: 18, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2015
[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation and Apoptosis of Lung Adenocarcinoma Cell H1975]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015, Oct-20, Volume: 18, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Epoxy Compounds; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phenanthrenes; Protein Kinase Inhibitors; Quinazolines	2015
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma. Medicine, 2016, Volume: 95, Issue:2 Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome	2016
Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest. Molecular medicine reports, 2016, Volume: 13, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Saponins	2016
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR. Oncotarget, 2016, Mar-29, Volume: 7, Issue:13 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines	2016
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. International journal of oncology, 2016, Volume: 48, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta	2016
Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance. Chinese medical journal, 2016, Apr-05, Volume: 129, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Female; Fever; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nivolumab; Quinazolines	2016
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. The journal of medical investigation : JMI, 2016, Volume: 63, Issue:1-2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed	2016
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncology reports, 2016, Volume: 36, Issue:1 Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2016
A genetic cell context-dependent role for ZEB1 in lung cancer. Nature communications, 2016, 07-26, Volume: 7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-3; Receptor, Notch1; Reproducibility of Results; Smoking; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1	2016
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report. World journal of surgical oncology, 2016, Jun-29, Volume: 14, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed	2016
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular cancer therapeutics, 2016, Volume: 15, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, IGF Type 1; Receptors, Death Domain; Receptors, Somatomedin; Signal Transduction; Smad2 Protein; Smad3 Protein; Somatomedins	2016
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations. Advances in experimental medicine and biology, 2016, Volume: 926 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People	2016
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene, 2017, 03-23, Volume: 36, Issue:12 Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3	2017
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 103 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases. Journal of orthopaedic surgery (Hong Kong), 2016, Volume: 24, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteogenesis; Pelvic Bones; Quinazolines; Spine	2016
Reply to C.-H. Chang et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 04-20, Volume: 35, Issue:12 Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans	2017
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 04-20, Volume: 35, Issue:12 Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines	2017
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed	2011
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibody Specificity; ErbB Receptors; Female; Gefitinib; Genetic Association Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Point Mutation; Quinazolines; Sequence Deletion	2011
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integrative cancer therapies, 2011, Volume: 10, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2011
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer, 2011, Jul-15, Volume: 117, Issue:14 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Smoking; X-ray Repair Cross Complementing Protein 1	2011
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure	2011
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed	2011
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. Journal of proteomics, 2011, Jun-10, Volume: 74, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry	2011
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids	2011
[Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2011, Volume: 14, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction	2011
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines	2011
Molecular selection trumps clinical selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome	2011
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. The European respiratory journal, 2012, Volume: 39, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA	2012
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. British journal of cancer, 2011, Jul-26, Volume: 105, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays	2011
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. Journal of cellular biochemistry, 2012, Volume: 113, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay	2012
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion	2012
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome	2012
[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT]. Zhonghua yi xue za zhi, 2011, Nov-01, Volume: 91, Issue:40 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cone-Beam Computed Tomography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome	2011
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids	2012
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta pharmacologica Sinica, 2012, Volume: 33, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors	2012
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer discovery, 2011, Volume: 1, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins	2011
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation]. No shinkei geka. Neurological surgery, 2012, Volume: 40, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt	2012
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window. Biomedical microdevices, 2012, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine	2012
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate	2012
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clinical lung cancer, 2013, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry	2013
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Malaysia; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2012
Survival of lung adenocarcinoma patients with malignant pleural effusion. The European respiratory journal, 2013, Volume: 41, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome	2013
Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. The Tohoku journal of experimental medicine, 2012, Volume: 228, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polyphosphates; Quinazolines; Radionuclide Imaging; Technetium Compounds; Tomography, X-Ray Computed; Treatment Outcome	2012
The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies	2012
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2012
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World journal of surgical oncology, 2012, Nov-07, Volume: 10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2012
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells. Anticancer research, 2012, Volume: 32, Issue:12 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays	2012
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2013